GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (LTS:0JDK) » Definitions » EV-to-FCF

Iovance Biotherapeutics (LTS:0JDK) EV-to-FCF : -9.40 (As of May. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Iovance Biotherapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Iovance Biotherapeutics's Enterprise Value is $3,610.11 Mil. Iovance Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-384.11 Mil. Therefore, Iovance Biotherapeutics's EV-to-FCF for today is -9.40.

The historical rank and industry rank for Iovance Biotherapeutics's EV-to-FCF or its related term are showing as below:

LTS:0JDK' s EV-to-FCF Range Over the Past 10 Years
Min: -10.67   Med: -4.32   Max: -1.42
Current: -9.4

During the past 13 years, the highest EV-to-FCF of Iovance Biotherapeutics was -1.42. The lowest was -10.67. And the median was -4.32.

LTS:0JDK's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs LTS:0JDK: -9.40

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Iovance Biotherapeutics's stock price is $13.72. Iovance Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.880. Therefore, Iovance Biotherapeutics's PE Ratio for today is At Loss.


Iovance Biotherapeutics EV-to-FCF Historical Data

The historical data trend for Iovance Biotherapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics EV-to-FCF Chart

Iovance Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.32 -24.76 -9.66 -2.60 -4.89

Iovance Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.60 -2.48 -3.98 -2.34 -4.89

Competitive Comparison of Iovance Biotherapeutics's EV-to-FCF

For the Biotechnology subindustry, Iovance Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's EV-to-FCF falls into.



Iovance Biotherapeutics EV-to-FCF Calculation

Iovance Biotherapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3610.108/-384.11
=-9.40

Iovance Biotherapeutics's current Enterprise Value is $3,610.11 Mil.
Iovance Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-384.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Iovance Biotherapeutics  (LTS:0JDK) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Iovance Biotherapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.72/-1.880
=At Loss

Iovance Biotherapeutics's share price for today is $13.72.
Iovance Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.880.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Iovance Biotherapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics (LTS:0JDK) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics (LTS:0JDK) Headlines

No Headlines